down arrow

Shield Therapeutics Plc

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: GB00BYV81293
  • LON: STX
GBP
0.05
0.00 (0.00%)

Sep 22

LON

 View all stocks in this country
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Shield Therapeutics Plc
ECO Animal Health Group Plc
Arecor Therapeutics Plc
Redx Pharma Plc
Indivior PLC
GSK Plc
AstraZeneca PLC
Destiny Pharma Plc
Alliance Pharma Plc
Benchmark Holdings Plc
Dechra Pharmaceuticals Plc

Why is Shield Therapeutics Plc ?

1
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
  • Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -16.41
2
The company has declared Positive results for the last 4 consecutive quarters
  • OPERATING CASH FLOW(Y) Highest at GBP -9.55 MM
  • DEBTORS TURNOVER RATIO(HY) Highest at 2.9 times
  • NET SALES(Q) Highest at GBP 22.58 MM
3
Risky -
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of -40.88%, its profits have risen by 37%
4
Below par performance in long term as well as near term
  • Along with generating -40.88% returns in the last 1 year, the stock has also underperformed FTSE 100 in the last 3 years, 1 year and 3 months
stock-recommendationReal-Time Research Report

Verdict Report

How much should you hold?

  1. Overall Portfolio exposure to Shield Therapeutics Plc should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Shield Therapeutics Plc for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
Shield Therapeutics Plc
-37.91%
1.51
72.01%
FTSE 100
16.06%
1.40
11.82%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
29.36%
EBIT Growth (5y)
-209.41%
EBIT to Interest (avg)
-14.46
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-14.69
Sales to Capital Employed (avg)
1.77
Tax Ratio
5.65%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-6.25
EV to EBIT
-10.92
EV to EBITDA
-12.28
EV to Capital Employed
32.80
EV to Sales
2.23
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-300.29%
ROE (Latest)
Negative BV
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
Bullish
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
Mildly Bearish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

21What is working for the Company
OPERATING CASH FLOW(Y)

Highest at GBP -9.55 MM

DEBTORS TURNOVER RATIO(HY)

Highest at 2.9 times

NET SALES(Q)

Highest at GBP 22.58 MM

OPERATING PROFIT(Q)

Highest at GBP 0.51 MM

OPERATING PROFIT MARGIN(Q)

Highest at 2.27 %

PRE-TAX PROFIT(Q)

Highest at GBP -1.53 MM

NET PROFIT(Q)

Highest at GBP -1.67 MM

RAW MATERIAL COST(Y)

Fallen by -29.76% (YoY

EPS(Q)

Highest at GBP -0

-1What is not working for the Company
INVENTORY TURNOVER RATIO(HY)

Lowest at 3.66 times

Here's what is working for Shield Therapeutics Plc

Net Sales
Highest at GBP 22.58 MM and Grown
In each period in the last five periods
MOJO Watch
Near term sales trend is very positive

Net Sales (GBP MM)

Operating Profit
Highest at GBP 0.51 MM and Grown
In each period in the last five periods
MOJO Watch
Near term Operating Profit trend is quite positive

Operating Profit (GBP MM)

Operating Profit Margin
Highest at 2.27 % and Grown
In each period in the last five periods
MOJO Watch
Company's profit margin has improved

Operating Profit to Sales

Pre-Tax Profit
Highest at GBP -1.53 MM and Grown
In each period in the last five periods
MOJO Watch
Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (GBP MM)

Net Profit
Highest at GBP -1.67 MM and Grown
In each period in the last five periods
MOJO Watch
Near term Net Profit trend is very positive

Net Profit (GBP MM)

Debtors Turnover Ratio
Highest at 2.9 times and Grown
In each half year in the last five Semi-Annual periods
MOJO Watch
Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Operating Cash Flow
Highest at GBP -9.55 MM
in the last three years
MOJO Watch
The company has generated higher cash revenues from business operations

Operating Cash Flows (GBP MM)

Net Sales
At GBP 22.58 MM has Grown at 36.51%
Year on Year (YoY)
MOJO Watch
Near term sales trend is positive

Net Sales (GBP MM)

Pre-Tax Profit
At GBP -1.53 MM has Grown at 78.88%
Year on Year (YoY)
MOJO Watch
Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (GBP MM)

Net Profit
At GBP -1.67 MM has Grown at 77.22%
Year on Year (YoY)
MOJO Watch
Near term Net Profit trend is positive

Net Profit (GBP MM)

EPS
Highest at GBP -0
in the last five periods
MOJO Watch
Increasing profitability; company has created higher earnings for shareholders

EPS (GBP)

Raw Material Cost
Fallen by -29.76% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Shield Therapeutics Plc

Inventory Turnover Ratio
Lowest at 3.66 times
in the last five Semi-Annual periods
MOJO Watch
Company's pace of selling inventory has slowed

Inventory Turnover Ratio

Footer loading